Major Breakthrough: Stanford Scientists Regenerate Cartilage with Single Injection
Researchers at Stanford Medicine have made a groundbreaking discovery, as published in the esteemed journal Science (June 12, 2026). This revolutionary study could drastically change the treatment approach for millions of arthritis and joint pain sufferers worldwide.
The study reveals that a single injection, inhibiting an aging-related enzyme known as 15-PGDH (colloquially referred to as a “gerozyme”), can entirely reverse cartilage loss in older mice. This treatment also prevents arthritis from forming post-knee injuries and initiates early signs of regeneration in human knee tissue obtained from replacement surgeries.
The research, spearheaded by Dr. Helen Blau, director of the Baxter Laboratory for Stem Cell Biology at Stanford, and Dr. Nidhi Bhutani, professor of orthopedic surgery, contradicts the long-standing medical assumption that adult cartilage is incapable of significant self-repair. The findings suggest a future where biological therapy could replace invasive joint replacement surgery—a procedure performed more than 700,000 times annually in the United States alone.
While this breakthrough is still in the research phase, Phase 1 clinical trials of a 15-PGDH inhibitor for muscle weakness have already confirmed its safety in healthy human volunteers. This gives scientists hope that a similar trial for cartilage regeneration could commence shortly. For the estimated hundreds of millions globally suffering from osteoarthritis, this discovery could signal a new era in joint health and anti-aging medicine.